Join the SmallCapReview mailing list.

AUPH Aurinia Pharmaceuticals: A late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.  More. 
MYGN Myriad Genetics: A  personalized medicine company, that focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. MYGN has a collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx.    More.
Commentary

Why 3200 On The S&P 500 Means Big Gains For Small Caps


Small Caps Punch Above Their Weight


Aurinia (AUPH) Reports Second Quarter Results


Small Cap Returns Are Leading


How To Invest In Small Caps Today


Markets
Volume Leaders
Advancers/Decliners
52 Week Highs/Lows
Small-Cap Index
Tools
Check Futures Here
Quotes
Level II Quotes
Stock Screener
Performance by Industry
Pre-Market
After Hours Market
World Markets
Education

 

Visit Our Resources Page

Past Articles Worth Reading

 

 

 

 


 

 

 

 

 

 

 Where Small Cap Stocks Thrive Since 1999                                           

3 Overlooked Small Caps


Small Cap Stocks And Retail Among Top Picks

Small Cap Growth Funds Are Now Up 23% For The Year

Small Caps Are Rising, Biotechs Can't Be Far Behind

Small Caps Kept It Rolling In August

Small Caps Rising Through Year End

Small Cap 600, Tracking The Technicals

Hustle And Russell, Small Caps Hit All Time High

Small Cap Stocks Continue To Set New Highs

Small Cap Growth Extends Dominance In One Year Returns

Small Cap Stocks Still Rule, Can Market Keep Going Up?

The Strong Case For Small Caps In Today's Market

Small Caps To Watch

Small Cap IR By The Numbers Average Small Cap IR budget: $224,000, with $78,000 spent on external services.


Myriad Genetics (MYGN)

Website: www.Myriad.com

"Myriad has the deepest diagnostic pipeline across the disease spectrum."

More on MYGN here...


Aurinia Pharmaceuticals (AUPH)

 

Website: www.Auriniapharma.com

"Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe."

More on AUPH here...


Follow Us On

Twitter


Small Cap Zombies Go Nowhere But Up


How Trade War Fears Are Boosting Small Caps


Why Investors Are Shifting To Small Cap Stocks


3 Reasons For The Small Cap Boom


Small Caps Lead Performance Year To Date


Small Stocks Dominate The Battle For Highest Returns


50 Best Performing Stocks In The S&P 600 Small Cap Index


Investors Return Home As Small Caps Lead The Way


Small Caps Beating  Large By Most In 16 Years


Tech And Small Caps At All Time High


Are Small Cap Growth Stocks The New Market Leaders?


Small Cap Stocks Could Rise To All-Time High


Small Cap Rally Could Add Another 10% or More


Small Cap Breakout


10 Small Caps With Large Cap Potential


Small Caps Hold Up Despite Market Swoon


4 Undervalued Small Caps


Why Small And Mid Caps Could Be The Answer To Trade Jitters


Why Small Cap Indexes Are An Economic Baromete


10 Winners And 10 Losers In The Small Cap Sector


Small Cap Markets Recover


Hottest Small Caps Of 2018


Russell 2000 Has Posted Gains For Six Straight Weeks


Small Caps Are Trouncing Large Cap Rivals


Small Cap Stock Boom Spurs Most Inflows Since Trump Victory


Yields On The Rise, While Small Caps Shine


Small Caps Lead The Way


Small Cap Equities Get Their Mojo Back


Small Caps Ready To Lead


Small Caps: The Bright Spot In A Challenging Market


Small Increase In Rates And Inflation Good For Small Caps


Small Cap Stocks Are Outperforming And The Run May Continue


Small Cap Stocks Top Large Caps Year To Date



Subscribers to our Free newsletter will receive stock reports and news alerts for small-cap stocks via email. You can sign-up here.


"A Primer In Small Cap Investing"

SmallCapReview.com® is a leading destination for small-cap picks and news. The Purpose of SmallCapReview.com is to profile and bring awareness to companies with a market cap of less than $1 billion, these small-cap stocks will primarily trade on the Nasdaq Small-Cap market. We also issue daily small cap stocks to watch via various newswires. We will strive to bring you the undiscovered, the undervalued, and the oversold. SmallCapReview.com does not give "buy" recommendations, price targets nor suggest entry and exit points.

"A Look at Small Cap Stocks that may no longer be Small Caps"


 

 

 


 
© 1999-2018 SmallCapReview.com. Any questions or comments regarding this site should be directed to editor@smallcapreview.com